表纸
市场调查报告书

癌症治疗PARP抑制剂市场:价格、剂量、临床Pipeline展望

Global PARP Inhibitors Cancer Therapy Market, Price, Dosage & Clinical Pipeline Outlook 2023

出版商 KuicK Research 商品编码 628063
出版日期 内容资讯 英文 200 Pages
商品交期: 最快1-2个工作天内
价格
癌症治疗PARP抑制剂市场:价格、剂量、临床Pipeline展望 Global PARP Inhibitors Cancer Therapy Market, Price, Dosage & Clinical Pipeline Outlook 2023
出版日期: 2018年04月20日内容资讯: 英文 200 Pages
简介

本报告研究全球PARP抑制剂市场市场,详细分析市场现况、动向、动态、影响市场的近年进步,汇整治疗药物价格、销售、每位病患的治疗成本、市场未来预测等情报。

第1章 Poly (ADP-Ribose) 聚合□抑制剂简介

  • 作为独特癌症治疗药物的PARP抑制剂
  • PARP抑制剂进步方面
  • PARP蛋白质 & 抑制剂准备阶段

第2章 PARP蛋白质:开发癌症治疗药物的具吸引力标靶

  • PARP抑制剂标靶部位结构组织
  • PARP抑制剂结构组织

第3章 正常细胞及癌症细胞中的PARP作用之治疗性开发

  • 正常细胞中的PARP蛋白质重要性
  • 肿瘤形成中的PARP蛋白质重要性:对细胞分裂及DNA修复的影响
  • PARP抑制剂:消除癌细胞的不同作用机制

第4章 全球Poly (ADP-Ribose) 聚合□抑制剂临床Pipeline概要

第5章 作为癌症单一药物治疗的Poly (ADP-Ribose)聚合□抑制剂 (PARP抑制剂)

  • Olaparib
  • Rucaparib
  • Niraparib
  • 临床Pipeline具潜力PARP抑制剂:有效性、剂量、预估价格

第6章 全球癌症治疗的PARP抑制剂:市场现况

  • PARP抑制剂市场概要
  • 市场区分:专利
  • 市场区分:药物销售
  • 市场趋势

第7章 传统癌症治疗的PARP抑制剂:有效性、剂量、价格分析

  • 化学疗法的PARP抑制剂
  • 结合放射治疗的PARP抑制剂

第8章 最新癌症治疗的PARP抑制剂有效性改善

  • PARP抑制剂及标靶治疗的结合
  • 结合免疫疗法的PARP抑制剂

第9章 推动全球PARP抑制剂市场的因素

  • 数种PARP抑制剂的连续核准及预期未来通过核准者
  • 强力临床Pipeline
  • 庞大病患基础
  • 已核准PARP抑制剂的商业成功

第10章 全球PARP抑制剂市场课题

  • 科学局限及副作用的数量
  • 繁复的核准流程

第11章 全球PARP抑制剂市场未来预测

  • Pipeline的PARP抑制剂

第12章 全球PARP抑制剂临床Pipeline:按企业、症状、阶段

  • 前临床
  • 临床
  • PhaseI
  • PhaseI/II
  • PhaseII
  • PhaseIII

第13章 已上市癌症治疗PARP抑制剂临床考察:按企业、症状

  • Olaparib (Lynparza)
  • Niraparib (Zejula)
  • Rucaparib (Rubraca)

第14章 竞争环境

  • 2X Oncology
  • Abott Laboratories
  • Cephalon
  • Checkpoint Therapeutics
  • Eisai Co. Ltd
  • IMPACT Therapeutics
  • Jeil Pharmaceuticals
  • KuDOS Pharmaceuticals
  • Kyowa Hakko Kirin
  • Lead Therapeutics
  • Shanghai De Novo Pharmatech
目录

Report highlights:

  • Current Market Trends & Development Scenario
  • Drug Availability, Dosage & Treatment Schedule
  • Commercially Available Drugs Price Analysis
  • Global Cancer PARP Inhibitors Clinical Pipeline Overview: 31 Drugs
  • Clinical & Patent Insight on Commercially Available Drugs: 3 Drugs
  • Market Segmentation by Drug Patent & Deals

Conventional therapies like surgery, radiotherapy and chemotherapies are currently the dominant form of cancer treatment globally. However, majority of these methods have several limitations with multiple adverse effects which has led to the emergence of much more innovative approach, collectively known as targeted therapies. Targeted cancer therapy segment currently flourishes with several types of therapeutics among which PARP inhibitors have gained immense popularity due to their superior efficacy to conventional therapeutics.

Inhibitors include drugs or substances that block the growth and spread of cancer by interfering with specific molecular targets that are involved in the growth, progression, and spread of cancer. PARP inhibitors are recent entrants in the targeted therapy segment which have gained worldwide popularity as the most common type treatment in certain clinical indications like ovarian cancer and breast cancer.

Poly-ADP Ribose Polymerase or PARP are special proteins that play a key role in assisting damaged cells to repair themselves. The initial clinical testing of PARP inhibitors began nearly a decade ago, following the discovery that these agents in vitro had heightened anticancer activity in cancer cells that harbored BRCA mutations compared to BRCA wild-type cancer cells with intact DNA repair.

Research proved that fault in either of BRCA 1 and BRCA 2 genes have an increased risk of certain types of cancer such as breast cancer, ovarian cancer and prostate cancer. Cells are less likely to repair themselves if there is a fault in one or both of these genes. Blocking PARP with a PARP inhibitor showed impressive results in preventing the proliferation of cancer cells by interfering with their DNA repair mechanism and killing them, thus resulting in a therapeutic outcome.

Currently, there are 3 PARP inhibitors that have been approved for use in patients with suspected or confirmed BRCA-mutated advanced ovarian cancer that has been treated with 3 or more prior lines of chemotherapy. Olaparib (Lynpraza) was the first PARP inhibitor to receive approval in 2014 followed by Rucaparib in 2016 and Niraparib in 2017.

Trends show that the cancer therapy market is steadily shifting from conventional therapeutics to modern therapeutics due to their better safety, efficacy and specificity; thus creating an excellent opportunity for promising therapeutics like PARP inhibitors.

PARP inhibitors have proved to be a commercial success in the modern cancer therapeutic segment. For instance, Lynpraza(Olaparib), marketed by AstraZeneca reported global sales of over US$ 400 Million in 2017; making it one of the most profitable cancer therapy drugs of the year. Lynpraza sales have more than doubled since its approval which projects an optimistic growth in the future. Olaparib is followed by Niraparib with sales of over US$ 109 Million during first nine months of commercial launch. Rucaparib - the most recent PARP inhibitor to enter the market is estimated to generate revenue of over US$ 40 Million by the end of 2018.

The US currently dominates the global PARP inhibitors market leading both in marketing and research followed by Europe. Involvement of regions like South Korea, Japan and Middle East has led to better market penetration and overall better market growth.

The demand for PARP inhibitors has grown exponentially with the increasing incidence of cancer. Further, their enhanced efficacy in cancer treatment when combined with conventional therapeutics like chemotherapy and radiation therapy has led to an exponential growth in sales; which is further strengthened by a robust clinical pipeline under development. With several favorable factors paving the path for success, PARP inhibitors could be one of the leading cancer therapeutics of the future

KuicK Research Analysis of the global PARP inhibitors market provides an in-depth analysis of the current market scenario, trends, dynamics and recent advances that might have an impact on the PARP inhibitors market. Key data like pricing of drugs, sales and cost of therapy per patient have been used to draw an accurate analysis of the PARP inhibitors market. Finally, KuicK Research analysis of forecast and projections regarding the future of PARP Inhibitors market indicate an exciting opportunity waiting in this highly profitable segment of cancer therapy.

Table of Contents

1. Introduction to Poly (ADP-Ribose) Polymerase Inhibitors

  • 1.1 PARP Inhibitors as Unique Cancer Therapy
  • 1.2 Evolutionary Aspects of PARP Inhibitors
  • 1.3 Prelude to PARP Proteins & their Inhibitors

2. PARP Proteins: An Attractive Target for Developing Cancer Therapeutics

  • 2.1 Structural Organization of Target Site of PARP Inhibitors
  • 2.2 Structural Organization of PARP Inhibitors

3. Therapeutic Exploitation of Role of PARP Proteins in Normal Cells & Cancer Cells

  • 3.1 Significance of PARP Proteins in Normal Cells
  • 3.2 Significance of PARP Proteins in Tumorigenesis: Affecting Cell Division & DNA Repair
  • 3.3 PARP Inhibitors: Distinct Modes of Action for Eliminating Cancer Cells

4. Global Poly (ADP-Ribose) Polymerase Inhibitors Clinical Pipeline Overview

5. Commercially Available Poly (ADP-Ribose) Polymerase Inhibitors (PARP Inhibitors) as Cancer Monotherapy

  • 5.1 Olaparib
    • 5.1.1 Availability, Dosage & Treatment Schedule
    • 5.1.2 Price Analaysis
  • 5.2 Rucaparib
    • 5.2.1 Availability, Dosage & Treatment Schedule
    • 5.2.2 Price Analysis
  • 5.3 Niraparib
    • 5.3.1 Availability, Dosage & Treatment Schedule
    • 5.3.2 Price Analysis
  • 5.4 Promising PARP Inhibitors in Clinical Pipeline: Efficiency, Dosage & Expected Price
    • 5.4.1 Talazoparib
    • 5.4.2 Veliparib

6. Global PARP Inhibitor Cancer Therapy Current Market Scenario

  • 6.1 PARP Inhibitor Market Outline
  • 6.2 Market Segmentation by Patent
  • 6.3 Market Segmentation by Drug Sales
  • 6.4 Market Trends

7. PARP Inhibitors with Conventional Cancer Therapy: Efficacy, Dosage & Price Analysis

  • 7.1 PARP Inhibitors with Chemotherapy
    • 7.1.1 Temozolomide
    • 7.1.2 Platinum Salts
    • 7.1.3 Taxanes
    • 7.1.4 Gemcitabine
    • 7.1.5 Topoisomerase Inhibitors/Poisons
  • 7.2 PARP Inhibitors in Combination with Radiotherapy

8. Improved Efficacy of PARP Inhibitors by Modern Cancer Therapies

  • 8.1 Combination of PARP Inhibitors & Targeted Therapies
    • 8.1.1 PARP Inhibitors with EGFR Inhibitors
    • 8.1.2 PARP Inhibitors with VEGFR Inhibitors
    • 8.1.3 PARP Inhibitors with PI3K/mTOR Inhibitors
    • 8.1.4 PARP Inhibitors with Trastuzumab
    • 8.1.5 Anti-endocrine agents
    • 8.1.6 HSP90 Inhibitors
    • 8.1.7 IGF-1R & HDAC Inhibitors
  • 8.2 PARP Inhibitors in Combination with Immunotherapies

9. Factors Driving Global PARP Inhibitors Market

  • 9.1 Consecutive Approvals of Several PARP Inhibitors & Anticipated Approvals in the Nearby Future
  • 9.2 Strong clinical Pipeline
  • 9.3 Large Patient Base
  • 9.4 Commercial Success of Approved PARP Inhibitors

10. Global PARP Inhibitor Market Challenges

  • 10.1 Scientific Limitations and the Number of Side Effects
  • 10.2 Tedious approval process

11. Global PARP Inhibitors Market Future Forecast

  • 11.1 PARP Inhibitors in the Pipeline: Shaping the Future of Ineffectively Treated Cancer
    • 11.1.1 PARP Inhibitors for Prostate Cancer
    • 11.1.2 PARP Inhibitors for Lung Cancer
    • 11.1.3 PARP Inhibitors in Pancreatic Cancer
    • 11.2 Market Opportunity

12. Global Cancer PARP Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 12.1 Preclinical
  • 12.2 Clinical
  • 12.3 Phase-I
  • 12.4 Phase-I/II
  • 12.5 Phase-II
  • 12.6 Phase-III

13. Marketed Cancer PARP Inhibitors Clinical Insight by Company & Indication

  • 13.1 Olaparib (Lynparza)
  • 13.2 Niraparib (Zejula)
  • 13.3 Rucaparib (Rubraca)

14. Competitive Landscape

  • 14.1 2X Oncology
  • 14.2 Abott Laboratories
  • 14.3 Cephalon
  • 14.4 Checkpoint Therapeutics
  • 14.5 Eisai Co. Ltd
  • 14.6 IMPACT Therapeutics
  • 14.7 Jeil Pharmaceuticals
  • 14.8 KuDOS Pharmaceuticals
  • 14.9 Kyowa Hakko Kirin
  • 14.10 Lead Therapeutics
  • 14.11 Shanghai De Novo Pharmatech

List of Figures

  • Figure 1-1: History & Evolution of PARP Inhibitors
  • Figure 1-2: Biochemistry & Biological Functions Of Poly ADP-Ribosylation Reaction Mediated by Poly (ADP-Ribose) Polymerase (PARP) Enzymes
  • Figure 2-1: Structural Organization of PARP-1 & PARP-2 Enzymes
  • Figure 3-1: PARP Proteins in DNA Damage Repair Mechanism
  • Figure 3-2: Importance of PARP in DNA Repair Mechanism in Normal Cells
  • Figure 3-3: Dual Action of PARP inhibition for Cancer Treatment
  • Figure 4-1: Global - Cancer PARP Inhibitors Pipeline by Phase (%), 2018 till 2023
  • Figure 4-2: Global - Cancer PARP Inhibitors Pipeline by Phase (Number), 2018 till 2023
  • Figure 4-3: Global - Cancer PARP Inhibitors Pipeline by Phase (%),2018 till 2023
  • Figure 4-4: Global - Cancer PARP Inhibitors Pipeline by Phase (Number), 2018 till 2023
  • Figure 5-1: Progression Free Survival in Patients with Platinum-Sensitive, Relapsed, BRCA-mutant Ovarian Cancer by Using a PARP Inhibitor for 30 Months
  • Figure 5-2: Olaparib - Available Concentrations (mg), 2018
  • Figure 5-3: Olaparib - Dosage Analysis (mg/Day)
  • Figure 5-4: Olaparib - 150mg & 100mg Tablet Dosage Analysis (mg/12 hour) By Tablet Concentration
  • Figure 5-5: Olaparib - 50mg Tablet Dosage Analysis (Number of Capsules/Day)
  • Figure 5-6: Olaparib - Price Analysis by Type (US$/Unit), 2018
  • Figure 5-7: Olaparib - Price Analysis by Type (US$/Packet), 2018
  • Figure 5-8: Olaparib - Average Price Analysis for Breast & Ovarian Cancer Treatment (US$), 2018
  • Figure 5-9: Olaparib - Ovarian Cancer Maintenance Therapy Cost Analysis for Reoccurent BRCA Mutated Population (US$), 2018
  • Figure 5-10: Olaparib - Total Cost Analysis for Ovarian Cancer Maintenance Therapy for Reoccurent BRCA Mutated Population (US$), 2018
  • Figure 5-11: Olaparib - Ovarian Cancer Maintenance Therapy Cost Analysis for Platinum Sensitive Germline BRCA Mutated Cancer Population (US$), 2018
  • Figure 5-12: Rucaparib - Available Concentrations of Drug (mg)
  • Figure 5-13: Rucaparib - Dosage Analysis (mg/Day), 2018
  • Figure 5-14: Rucaparib - 300mg & 200mg Tablet Dosage Analysis (mg/12 hour) By Tablet Concentration
  • Figure 5-15: Rucaparib - Price Analysis (US$), 2018
  • Figure 5-16: Rucaparib - Average Price Analysis for Reoccurent BRCA Mutated Cancer Treatment (US$), 2018
  • Figure 5-17: Rucaparib - Ovarian Cancer Maintenance Therapy Cost Analysis for Reoccurent BRCA Mutated Population (US$), 2018
  • Figure 5-18: Rucaparib - Total Cost Analysis for Maintenance Therapy for Reoccurent BRCA Mutated Cancer Population (US$), 2018
  • Figure 5-19: Niraparib - Dosage Analysis (mg/Day)
  • Figure 5-20: Niraparib - Price Analysis (US$), 2018
  • Figure 5-21: Niraparib - Average Price Analysis for Breast & Ovarian Cancer Treatment (US$), 2018
  • Figure 5-22: Niraparib - Maintenance Therapy Cost Analysis for Germline BRCA Mutated Cancer Population (US$), 2018
  • Figure 5-23: Niraparib - Maintenance Therapy Cost Analysis for Non - Germline BRCA Mutated Cancer Population (US$), 2018
  • Figure 5-24: Niraparib - Complete Cancer Treatment Cost Analysis
  • Figure 5-25: Talazoparib - Upcoming Concentration (mg), 2018
  • Figure 5-26: Talazoparib - Expected Price Analysis by Concentration (US$), 2018
  • Figure 5-27: Veliparib - Treatment Course Analysis indicated in Clinical Trials
  • Figure 5-28: Veliparib - Dosage Analysis indicated in Clinical Trials (mg)
  • Figure 5-29: Overall Survival in Patients with Breast Cancer Treated with Carboplatin + Paclitaxel with Veliparib v/s without Veliparib (Months)
  • Figure 6-1: Global - Lynparza (Olaparib) Patent Approval & Expiration Year by Drug Form, 2018
  • Figure 6-2: Lynparza (Olaparib) - Number of Granted Patents & Applications, 2018
  • Figure 6-3: US - Lynparza (Olaparib) Patent Analysis by Number, 2018
  • Figure 6-4: Global - Lynparza (Olaparib) Patent Analysis by Approved Drug Formulations, 2018
  • Figure 6-5: Global - Rubraca (Rucaparib) Patent Aprroval & Expiration Year, 2018
  • Figure 6-6: Rucaparib (Rubraca) - Number of Granted Patents & Applications, 2018
  • Figure 6-7: Global - Zejula (Niraparib) Patent Approval & Expiration Year, 2018
  • Figure 6-8: Zejula (Niraparib) - Granted Patents & Applications, 2018
  • Figure 6-9: Global - Lynparza (Olaparib) Sales (US$ Million), 2015-2017
  • Figure 6-10: Global - Rubraca (Rucaparib) Sales (US$ Milion), 2017
  • Figure 6-11: Global - Zejula (Niraparib) Sales (US$ Million), Q1'2017 & Q2'2017
  • Figure 6-12: Global - PARP Inhibitors End Users (Number of Patients/Year), 2018
  • Figure 7-1: Tolerable Dosage of Rucaparib & Temozolomide Combination Therapy in Clinical Trials for Advanced Malignancy (mg/m2)
  • Figure 7-2: Study of Veliparib + Temozolomide Showing Improved Survival of Patients with Metastatic Melanoma (Months)
  • Figure 7-3: Estimated Glioblastoma Treatment Cost for Temozolomide + PARP Inhibitor Therapy, (US$/Cycle)
  • Figure 7-4: Olaprib & Paclitaxel Combination Therapy Dosage Analysis for Metastatic Gastric Cancer (mg/Day & mg/m2/Day)
  • Figure 7-5: Olaprib & Paclitaxel Combination Therapy Dosage Analysis for Metastatic Gastric Cancer (Administeration/Cycle)
  • Figure 7-6: Olaparib & Paclitaxel Combination Therapy Cost Analysis for Metastatic Gastric Cancer (US$/Cycle)
  • Figure 7-7: Overall Survival of Patients with Metastatic Gastic Cancer with Paclitaxel Chemotherapy vs Combination Therapy with Olaparib (Months)
  • Figure 7-8: Overall Survival in Patients with Triple-Negative Breast Cancer Treated with Gemiciabine & Carboplatin Chemotherapy vs Combination Therapy with Iniparib (Months)
  • Figure 8-1: Overall Progression Free Survival in Patients with Recurrent Platinum-Sensitive High-Grade Serous or Endometrioid Ovarian Cancer Treated with Cediranib + Olaparib v/s Olaparib Monotherapy (Months), 2018
  • Figure 8-2: Olaparib & Cediranib Combination Therapy Dosage Analysis as per Clinical Trials (mg/Day)
  • Figure 9-1: Expected Approval of PARP Inhibitors in the Nearby Future
  • Figure 11-1: US - PARP Inhibitor Market Opprtunity in Ovarian Cancer by Patient Base Undergoing Treatment
  • Figure 11-2: US - PARP Inhibitor Market Opprtunity in Breast Cancer by Patient Base Undergoing Treatment

List of Tables

  • Table 11-1: Ongoing Clinical Trials of PARP Inhibitor Combination Therapy for Prostate Cancer